top of page

Liquid biopsies

Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges (Review)

Trujillo B, et al. Br J Cancer. 2022


Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay

Orlando F, et al. NAR Cancer. 2022


Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study

Conteduca V, et al. Eur J Cancer. 2021


Circulating Androgen Receptor for Prognosis and Treatment Selection in Prostate Cancer

Conteduca V, et al. Eur Urol Oncol. 2021


Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial

Jayaram A, et al. Ann Oncol. 2021


Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer.

Conteduca V, et al. Br J Cancer. 2020


Genome-wide plasma DNA methylation features of metastatic prostate cancer

Wu A, et al. The Journal of Clinical Investigation. 2020

Multimodal Approach to Outcome Prediction in Metastatic Castration-Resistant Prostate Cancer by Integrating Functional Imaging and Plasma DNA Analysis

Conteduca V, et al. JCO Precision Oncology. 2019

Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis

Jayaram A, et al. JCO Precision Oncology. 2019

Plasma DNA Analysis in Prostate Cancer: Opportunities for Improving Clinical Management (Review)

Wu A, Attard G. Clin Chem. 2019.

Plasma DNA and Metastatic Castration-Resistant Prostate Cancer: The Odyssey to a Clinical Biomarker Test (Review)

Jayaram A, Wetterskog D, Attard G, Cancer Discov. 2018.

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer

Conteduca V, et al. European Urology. 2018

Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study

Conteduca V, et al. Ann Oncol. 2017

Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer

McDaniel AS, et al. BJU Int. 2017

Plasma AR and abiraterone-resistant prostate cancer

Romanel A, et al. Sci Transl Med. 2015

Androgen receptor expression in circulating tumour cells from castration resistant prostate cancer patients treated with novel endocrine agents

Crespo M, et al. Br J Cancer. 2015

Tumor clone dynamics in lethal prostate cancer

Carreira S, et al. Sci Transl Med. 2014

bottom of page